NovaBridge Biosciences (NBP)
| Market Cap | 242.86M +249.6% |
| Revenue (ttm) | n/a |
| Net Income | -88.34M |
| EPS | -0.92 |
| Shares Out | 115.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 792,716 |
| Open | 2.180 |
| Previous Close | 2.200 |
| Day's Range | 2.080 - 2.220 |
| 52-Week Range | 0.853 - 6.790 |
| Beta | 1.56 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+328.57%) |
| Earnings Date | Aug 21, 2026 |
About NBP
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NBP stock is "Strong Buy" and the 12-month stock price target is $9.0.
News
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commerci...
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology platform company committed to accelerating access to inn...
NovaBridge had ‘productive’ FDA meeting on potential gastric cancer treatment
The company states: “NovaBridge (NBP) Biosciences announced that based on a productive Type B meeting with the U.S. Food and Drug Administration and receipt of written minutes, NovaBridge has secured…
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
FDA confirmed givastomig's potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective resp...
NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted to a platform model leveraging China-U.S. synergies, with Givastomig showing strong efficacy and safety in gastric cancer and VIS-101 demonstrating superior durability in AMD. IPO plans are delayed pending regulatory and market conditions.
NovaBridge Biosciences Transcript: Status update
VIS-101, a novel bispecific antibody for retinal vascular diseases, demonstrated strong safety, rapid and durable efficacy, and superior durability compared to current therapies in phase IIa trials. A phase IIb dose-ranging study will start soon, with global phase III planned for 2027.
NovaBridge, Visara announce results from VIS-101 Phase 2a Wet AMD study
NovaBridge (NBP) Biosciences, a global biotechnology platform company committed to accelerating access to innovative medicines, and its subsidiary, Visara announced topline results from the Phase 2a s...
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet A...
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge appoints Cunningham as Vice Chairman of Board of Directors
NovaBridge (NBP) Biosciences named Emmett Cunningham, Jr, MD, PhD, MPH, Co-Founder and Executive Chairman of Visara, as Vice Chairman of the NovaBridge Board of Directors. Dr. Cunningham will also joi...
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
ROCKVILLE, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge enrolls first patient in givastomig combination study
NovaBridge (NBP) announced enrollment of the first patient in the global Phase 2 randomized combination study evaluating givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with niv...
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
ROCKVILLE, Md., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge resumed with a Buy at H.C. Wainwright
H.C. Wainwright resumed coverage of NovaBridge (NBP) with a Buy rating and price target of $9, up from $7. The firm says givastomig has the potential to be the best-in-class…
NovaBridge announces open market purchases by executive chairman Fu Wei
NovaBridge (NBP) Biosciences announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company’s ADSs in open market transactions. The purchases started on…
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge presents dose expansion data from Phase 1b study of givastomig
NovaBridge (NBP) Biosciences announced positive updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemoth...
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader
NovaBridge’s ragistomig shows anti-tumor efficacy in Phase 1 trial
NovaBridge (NBP) presentated new data from the expanded 3mg/kg every 6 week Phase 1 dosing study for ragistomig, a bispecific 4-1BB X PD-L1 antibody, in a poster at the ESMO-IO…
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
ROCKVILLE, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...